Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Journal of Clinical Oncology(2021)10.1200/jco.20.03579Source: DataRank Database

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study is a research paper published in Journal of Clinical Oncology (2021). On theSindex it has a DataRank of 0.832. It has been cited 256 times.

N/A

0.832DataRank · unranked

Scored on demand from live citation data

256 citations

Free full text

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 16.46)OA: bronzeTopics (47)IDs (PubMed, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.832

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (20)

Mehmet A. N. Şendur,Delvys Rodríguez‐Abreu ORCID,Keunchil Park ORCID,Dae Ho Lee ORCID,Irfan Çiçin ORCID

Live enrichment

PubMed:33513313 OpenAlex:https://openalex.org/W3124587416

FWCI

16.46

Citation Percentile

1.0%

Influential Citations

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: other-oa

journalhttps://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.03579

BRONZEhttps://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.03579

publisherhttps://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.03579

journalhttps://doi.org/10.1200/jco.20.03579

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33513313

Fields of Study

Cancer Immunotherapy and BiomarkersPeptidase Inhibition and AnalysisLung Cancer Diagnosis and TreatmentMedicineAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarcinoma, Non-Small-Cell LungDouble-Blind MethodFemaleHumansIpilimumabLung NeoplasmsMaleMiddle Aged

MeSH Terms

IpilimumabAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDouble-Blind MethodFemaleHumansLung NeoplasmsMaleMiddle AgedB7-H1 AntigenAntibodies, Monoclonal, Humanized

Keywords

PembrolizumabIpilimumabMedicineInternal medicinePlaceboLung cancerHazard ratioPopulationOncologyAdverse effectCancerSurgeryImmunotherapyConfidence intervalPathology

Sustainable Development Goals

SDG 0: Good health and well-being

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

FAIR Checklist

DataRank Breakdown

Authors (20)

Impact

Open Access

Topics

Annotations (Europe PMC)